Viewing Study NCT00470275



Ignite Creation Date: 2024-05-05 @ 5:30 PM
Last Modification Date: 2024-10-26 @ 9:32 AM
Study NCT ID: NCT00470275
Status: COMPLETED
Last Update Posted: 2014-10-20
First Post: 2007-05-03

Brief Title: Cytarabine in Treating Young Patients With Recurrent or Refractory Ewings Sarcoma
Sponsor: Childrens Oncology Group
Organization: Childrens Oncology Group

Study Overview

Official Title: Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWSFLI for Children and Young Adults With Recurrent or Refractory Ewing Sarcoma
Status: COMPLETED
Status Verified Date: 2014-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Drugs used in chemotherapy such as cytarabine work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing

PURPOSE This phase II trial is studying how well cytarabine works in treating young patients with recurrent or refractory Ewings sarcoma
Detailed Description: OBJECTIVES

Determine the response rate in younger patients with recurrent or refractory Ewings sarcoma treated with cytarabine

OUTLINE This is a multicenter study

Patients receive cytarabine IV over 2 hours twice daily on days 1-5 Treatment repeats every 21 days for up to 11 courses in the absence of disease progression or unacceptable toxicity

After completion of study treatment patients are followed periodically for 5 years

PROJECTED ACCRUAL A total of 20 patients will be accrued for this study

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
COG-AEWS0621 OTHER Childrens Oncology Group None
CDR0000542650 OTHER None None